Rituximab + Immunotherapy in Follicular Lymphoma
Summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
6 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- City of Hope
Duarte, California, United States
- Yale New-Haven Hospital
New Haven, Connecticut, United States
- Emory University
Atlanta, Georgia, United States
- University of Chicago
Chicago, Illinois, United States
- Dana Farber Cancer Institute
Boston, Massachusetts, United States
- Washington University in St. Louis
St Louis, Missouri, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 30 Oct 2018
- Primary completion
- 23 Jul 2021
- Completion
- 30 Jul 2023
- Last update posted
- 6 Feb 2025
- Registered enrollment
- 24
- Registry id
- NCT03636503
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.